Volume 77, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


The objective of this study was to evaluate the triazole anti-fungal agent, voriconazole, as therapy for systemic infections in patients with advanced HIV infection. Patients with systemic infection were enrolled into a study of voriconazole for the treatment of less common, emerging, or refractory fungal infections. Patients were eligible for inclusion in the study on the basis that no anti-fungal agents have received regulatory approval specifically for infections. Patients were treated in the hospital setting with intravenous voriconazole (6 mg/kg every 12 hours on Day 1 and then 4 mg/kg every 12 hours for at least 3 days, after which patients could switch to oral therapy at 200 mg twice a day) or as outpatients with oral voriconazole (400 mg twice a day on Day 1 and then 200 mg twice a day) for a maximum of 12 weeks. Eleven patients received treatment with voriconazole. Two received short courses of intravenous therapy followed by the oral formulation; nine were treated with oral voriconazole only. At the end of therapy, eight of the nine evaluable patients had favorable response to therapy, based on mycological and clinical findings. There were no relapses of infection in the six patients who were seen at follow-up within 4 weeks of the end of therapy. Treatment with voriconazole was well tolerated, with no discontinuations caused by drug-related adverse events. The results of this study suggest that voriconazole is an effective, well-tolerated, and convenient option for the treatment of systemic infections with .


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Cooper CR Jr, Haycocks NG, 2000. Penicillium marneffei: An insurgent species among the penicillia. J Eukaryot Microbiol 47 : 24–28. [Google Scholar]
  2. Sirisanthana T, Supparatpinyo K, 1998. Epidemiology and management of penicilliosis in human immunodeficiency virus-infected patients. Int J Infect Dis 3 : 48–53. [Google Scholar]
  3. Supparatpinyo K, Sirisanthana T, 1994. New fungal infections in the Western Pacific. JAMA Southeast Asia 10 (suppl 3): 208–209. [Google Scholar]
  4. Hien TV, Loc PP, Hoa NT, Duong NM, Quang VM, McNeil MM, 2001. First cases of disseminated penicilliosis marneffei infection among patients with acquired immunodeficiency syndrome in Vietnam. Clin Infect Dis 32 : e78–e80. [Google Scholar]
  5. Chaiwun B, Khunamornpong S, Sirivanichai C, Rangdaeng S, Supparatpinyo K, Settakorn J, 2002. Lymphadenopathy due to Penicillium marneffei infection: Diagnosis by fine needle aspiration cytology. Mod Pathol 15 : 939–943. [Google Scholar]
  6. Saadiah S, Jeffrey AH, Mohamed AL, 1999. Penicillium marneffei infection in a non AIDS patient: First case report from Malaysia. Med J Malaysia 54 : 264–266. [Google Scholar]
  7. Duong TA, 1996. Infection due to Penicillium marneffei, an emerging pathogen: Review of 155 reported cases. Clin Infect Dis 23 : 125–130. [Google Scholar]
  8. Supparatpinyo K, Chiewchanvit S, Hirunsri P, Baosoung V, Uthammachai C, Chaimongkol B, 1992. An efficacy study of itraconazole in the treatment of Penicillium marneffei infection. J Med Assoc Thai 75 : 688–691. [Google Scholar]
  9. Hilmarsdottir I, Meynard JL, Rogeaux O, Guermonprez G, Datry A, Katlama C, 1993. Disseminated Penicillium marneffei infection associated with human immunodeficiency virus: a report of two cases and a review of 35 published cases. J Acquir Immune Defic Syndr 6 : 466–471. [Google Scholar]
  10. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE, 2002. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 34 : 277–284. [Google Scholar]
  11. Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T, 1998. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med 339 : 1739–1743. [Google Scholar]
  12. Espinel-Ingroff A, Boyle K, Sheehan DJ, 2001. In vitro anti-fungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature. Mycopathologia 150 : 101–115. [Google Scholar]
  13. Espinel-Ingroff A, 2001. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 39 : 954–958. [Google Scholar]
  14. Espinel-Ingroff A, Steele-Moore L, 2001. In vitro activities of voriconazole against the mycelial and yeast forms of Penicillium marneffei by different testing conditions. Mycoses 44 : 17. [Google Scholar]
  15. Perfect JR, Marr KA, Walsh TJ, Greenberg R, Dupont B, de la Torre-Cisneros J, 2003. Voriconazole treatment for less common, emerging or refractory fungal infections. Clin Infect Dis 36 : 1122–1131. [Google Scholar]
  16. Supparatpinyo K, Nelson KE, Merz WG, Breslin BJ, Cooper CR Jr, Kamwan C, 1993. Response to anti-fungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother 37 : 2407–2411. [Google Scholar]
  17. Sirisanthana T, Supparatpinyo K, Perriens J, Nelson KE, 1998. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis 26 : 1107–1110. [Google Scholar]
  18. Marty F, Mylonakis E, 2002. Anti-fungal use in HIV infection. Expert Opin Pharmacother 3 : 91–102. [Google Scholar]
  19. Tassaneeyakul W, Tawalee A, Tassaneeyakul W, Kukongviriyapan V, Blaisdell J, Goldstein JA, Gaysornsiri D, 2002. Analysis of the CYP2C19 polymorphism in a Northeastern Thai population. Pharmacogenetics 12 : 221–225. [Google Scholar]

Data & Media loading...

  • Received : 22 Sep 2004
  • Accepted : 05 Apr 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error